retatrutide mechanism triple agonist glp-1 gip glucagon The power of three: Retatrutide's role in modern obesity and diabetes therapy A review of an investigational

It reduces appetite by targeting brain areas that control hunger, slows gastric emptying to extend feelings of fullness, and improves insulin sensitivity

Garg said that practitioners still need more data to understand the connection between GLP-1 medication use and these cases

Recent Developments: Continued expansion of Wegovy's indications, including applications for cardiovascular risk reduction

In conclusion, it is essential to strategically use both GLP-1RA and SGLT2i for cardiovascular prevention in ASCVD patients with type 2 diabetes by targeting HbA1c levels and achieving blood pressure control (Fig

Given that appetite and weight control will be key targets for an oral formulation, it is fortuitous that it is the stimulation of vagal afferents that has a direct impact on satiety effects of GLP1-RAs ( Statements Data availability statement The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author